Lombard Medical Technologies (LSE:LMT) ROE % Adjusted to Book Value : -23.48% (As of Dec. 2012)

View and export this data going back to . Start your Free Trial

What is Lombard Medical Technologies ROE % Adjusted to Book Value?

Lombard Medical Technologies's ROE % for the quarter that ended in Dec. 2012 was -199.59%. Lombard Medical Technologies's PB Ratio for the quarter that ended in Dec. 2012 was 8.50. Lombard Medical Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2012 was -23.48%.

Lombard Medical Technologies ROE % Adjusted to Book Value Historical Data

The historical data trend for Lombard Medical Technologies's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lombard Medical Technologies ROE % Adjusted to Book Value Chart

Lombard Medical Technologies Annual Data

Trend

Sep02

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-1,071.06

-86.95

-30.35

-45.71

-11.83

Lombard Medical Technologies Semi-Annual Data
	Sep02	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-1,343.41	-71.05	-22.20	-41.21	-23.48

Competitive Comparison of Lombard Medical Technologies's ROE % Adjusted to Book Value

For the Medical Instruments & Supplies subindustry, Lombard Medical Technologies's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lombard Medical Technologies's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lombard Medical Technologies's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lombard Medical Technologies's ROE % Adjusted to Book Value falls into.

Lombard Medical Technologies ROE % Adjusted to Book Value Calculation

Lombard Medical Technologies's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2012 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-100.53%	/	8.50
	=	-11.83%

Lombard Medical Technologies's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2012 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-199.59%	/	8.50
	=	-23.48%

Lombard Medical Technologies ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Lombard Medical Technologies's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Lombard Medical Technologies (LSE:LMT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lombard Medical Technologies PLC (LSE:LMT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.lombardmedical.com

Lombard Medical Technologies PLC is engaged in the design and development of endovascular stent grafts, their manufacture, and commercialization either directly through the group's own sales force or through a network of local distributors supported by clinical specialists from Lombard Medical. The principal product, the AorfixT AAA stent graft has European CE mark approval for use in patients with high-angle-neck aneurysms of up to 90 degrees. The group has operations in United Kingdom and United States of America.